ClinicalTrials.gg
Not yet recruitingNCT03217617Updated Nov 3, 2026

SCID-X1 Gene Therapy Via Intravenous Lentiviral (Ivlv-X1) Injection

A Phase 1/2 interventional study of Direct intravenous injection of ivlv-X1 lentiviral vector in SCID, X-Linked, sponsored by Shenzhen Geno-Immune Medical Institute. Not yet recruiting at 1 site in China. Open to male participants aged 1 Month to 1 Year. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Shenzhen Geno-Immune Medical Institute · Phase 1/2, Interventional, and Treatment

How we know

Updated Nov 3, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
1 Month to 1 Year
Sex
Male
01

Study summary

This is a Phase I/II gene therapy trial treating X-linked severe combined immunodeficiency (SCID-X1) using a self-inactivating lentiviral vector (ivlv-X1) to functionally correct the genetic defect. The primary objectives are to evaluate the safety and efficacy of the direct intravenous lentiviral gene transfer protocol.

Read the detailed description

Important Regulatory Notice:

This trial record is only for global academic information registration on ClinicalTrials.gov. Neither the sponsor Beijing Meikang Jimian Biotechnology Co., Ltd. nor collaborator Shenzhen Geno-Immune Medical Institute has obtained NMPA clinical trial approval or clinical technology filing permission to carry out interventional cell therapy trials in mainland China.

ClinicalTrials.gov registration alone does not represent legal approval by Chinese health and drug regulatory authorities.

X-linked severe combined immunodeficiency (SCID-X1) is a genetic disorder caused by defect in the common cytokine receptor chain, normally on the surface of lymphocytes. Individuals with SCID-X1 lack the normal development of a functional immune system and so have difficulty fighting infections, which may lead to chronic or severe illness and death. X-SCID patients are normally rescued by a bone marrow transplant from a healthy donor. This trial aims to treat SCID-X1 using a self-inactivating lentiviral vector (LV) carrying a functional gene to correct the genetic defect. By direct intravenous (iv) injection of the LV (ivlv-X1) to modify immune cells in the body, this treatment may establish normal healthy immune cells and overcome the immunodeficiency.

The primary objectives are to evaluate the safety of the self-inactivating ivlv-X1-LV, the in vivo gene transfer protocol and the efficacy of immune reconstitution in patients overcoming frequent infections present at the time of treatment, assessment of iv LV gene transfer efficiency, and finally the long-term correction of immunodeficiency.

02

Conditions studied

  • SCID, X-Linked

Keywords

  • SCID-X1
  • lentiviral vector
  • intravenous gene transfer
03

In context

X-Linked Combined Immunodeficiency Diseases

28 studies on the registry are indexed under X-Linked Combined Immunodeficiency Diseases; 9 are open to participants now.

This study's planned enrollment of 10 is above the median of 9 across 16 interventional studies indexed under X-Linked Combined Immunodeficiency Diseases.

Browse X-Linked Combined Immunodeficiency Diseases studies →

Lead sponsor

Shenzhen Geno-Immune Medical Institute is the lead sponsor of 70 studies on the registry; 44 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Month to 1 Year
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of SCID-X1 based on:

    • A proven mutation in the common interleukin-2 receptor gamma chain gene as defined by direct sequencing of patient DNA.
    • T-cell immune deficiency defined as one or more of the following: CD3+ autologous T cells \< 300/ul, or less than 50% of normal value for in vitro mitogen stimulation, or absent proliferation in vitro to antigen stimulation.
  2. No available HLA identical related donor.
  3. With severe infections, including but not limited to: pneumonitis; protracted diarrhea requiring total parenteral nutrition; infection with herpes viruses or adenovirus; disseminated BCG infection.
  4. No cytogenetic abnormalities (medullary karyotype) and no detection of main rearrangements associated with acute leukemia.
  5. No prior stem cell transplantation.
  6. ≥ 3 months.
  7. Documented to be negative for infection.
  8. Written, obtained prior to any study-specific procedures.

Exclusion criteria

Exclusion Criteria:

  1. No available molecular diagnosis confirming SCID-X1.
  2. Existence of an available HLA-identical related donor.
  3. Diagnosis of active malignant disease other than EBV-associated lymphoproliferative disease.
  4. Current treatment with any chemotherapeutic agent (becomes eligible if not on treatment for at least 1 month).
  5. Patients with evidence of infection with -1 or 2.
  6. Presence of a medical condition indicating that survival will be less than 4 weeks such as the requirement for mechanical ventilation, severe failure of a major organ system, or evidence of a serious, progressive infection that is to medical treatment.
  7. Current treatment with any agent, excluding .
  8. Patients, in the opinion of investigators, may not be eligible or not able to comply with the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Single arm

    In vivo LV gene transfer to treat SCID-X1

    Biological: Direct intravenous injection of ivlv-X1 lentiviral vector

Interventions

  • BiologicalDirect intravenous injection of ivlv-X1 lentiviral vector

    ivlv-X1 LV intravenous injection at a dose of \~1x10e9/kg body weight.

06

What researchers measure

Primary outcomes

  1. Overall survival

    Time frame: 1 year

  2. Overall immune reconstitution

    T and B cell recovery

    Time frame: 1 year

  3. Change of infection status

    Time frame: 1 year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2027; primary completion for Dec 2028, 18 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2017
First posted
Jul 14, 2017
StartEst.
Jun 30, 2027
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2029
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact's phone or email changed: c•••@szgimi.org→c•••@mkgimi.com. See the current contact
Nov 3, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Shenzhen Geno-immune Medical Institute · Shenzhen, ChinaContact c•••@szgimi.org→c•••@mkgimi.com
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Contact Study contact's phone or email changed: c•••@szgimi.org→c•••@mkgimi.com. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Shenzhen Geno-immune Medical Institute · Shenzhen, ChinaContact c•••@szgimi.org→c•••@mkgimi.com
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03217617
Lead sponsor
Shenzhen Geno-Immune Medical Institute
Responsible party
Lung-Ji Chang (President, Shenzhen Geno-Immune Medical Institute) — Principal investigator
First posted
Jul 14, 2017
Start date
Jun 30, 2027 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 3, 2026

Study contacts

Lung-Ji Chang, Ph.D
Contact
c@mkgimi.com
+86 0755-86573763
Lung-Ji Chang, Ph.D
principal investigator · Shenzhen Geno-Immune Medical Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion